Should You Invest In VBR?

I've often described value-based reimbursement (VBR) as “glacial”—moving slowly and changing everything in its path. Right now, 19% of provider reimbursements are paid through some type of contractual arrangement with downside financial risk.

But is VBR going to “stall out” or continue to grow. If you look at investor activity, investors are voting on growth in the model. And a recent Bain analysis, Value-Based Care: Opportunities Expand, singled out the best options as investing in the organizations that are participating in VBR models or in the services or technology that enable the VBR transition. This is . . .